Sun Pharma has initiated a voluntary recall of vials containing the drug vecuronium bromide that were found to be contaminated with glass particles. Vecuronium bromide is used as a muscle relaxant during surgery or ventilation and exposure to glass particles could cause local irritation, swelling, or blockage in blood vessels. To date, no adverse events have been reported related to this recall.

1. Recall of pharma packaging
By:
Dushyant Prajapati
Packaging development
Mob.: 9925163585

2. Recall of pharma packaging
Sun Pharma has initiated a voluntary recall of vials containing vecuronium bromide, after they were
found to be contaminated with glass.
Vecuronium Bromide for Injection is used as an adjunct to general anesthesia, to facilitate
endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical
ventilation and is packaged in a glass vial; ten vials per carton. Vecuronium Bromide for Injection
should be administered by or under the supervision of experienced clinicians and must be
reconstituted prior to use. The affected Vecuronium Bromide for Injection are few batches of 10 mg &
20 mg.
The administration of a glass particulate, if present in an intravenous drug, may result in local irritation
or swelling in response to the foreign material. More serious potential outcomes would include
blockage and clotting in blood vessels, which may be life-threatening. To date, SPII has not received
any reports of adverse events related to this recall.

3. Recall of pharma packaging
A pharmaceutical company is voluntarily recalling some birth control pills because they may be
packaged in the wrong order or may have an empty blister pocket. The recalled pills are made by
Apotex Corp.
A pharmaceutical company is voluntarily recalling some birth control pills because they may be
packaged in the wrong order or may have an empty blister pocket. Apotex Corp. is recalling four lots
of Drospirenone and Ethinyl Estradiol tablets USP, manufactured by Oman Pharmaceutical Products
Co. LLC. The affected tablet lots all expire in August 2020. The NDC number on the outer carton of the
recalled product is 60505-483-3; the NDC number on the inner carton is 60505-4183-1. The outer
carton contains three inner cartons; the inner carton contains one blister with 21 active, yellow color
tablets and seven placebo, white color tablets.

4. Recall of pharma packaging
Alvogen, Inc. is voluntarily recalling two lots of Fentanyl Transdermal System 12 mcg/h transdermal patches to the
consumer level. A small number of cartons labeled 12 mcg/h Fentanyl Transdermal System patches contained 50
mcg/h patches. The 50 mcg/h patches that were included in cartons labeled 12 mcg/h are individually labeled as 50
mcg/h. This transdermal system is manufactured by 3M Drug Delivery Systems, St. Paul, MN.
Application of a 50 mcg/h patch instead of a prescribed 12 mcg/h patch could result in serious, life threatening, or
fatal respiratory depression. Groups at potential increased risk could include first time recipients of such patches,
children, and the elderly. To date, Alvogen Inc. has not received any reports of adverse events related to this issue.
The product is indicated for the management of pain in opioid tolerant patients and is packaged in primary cartons of
five individually wrapped and labeled pouches. The affected Fentanyl Transdermal System lots include:
Lot 180060 of Fentanyl Transdermal System, 12 mcg/h, expiration date 05/2020. Lot 180073 of Fentanyl Transdermal
System, 12 mcg/h, expiration date 06/2020. The mislabeled product is packaged in a 12 mcg/h primary carton.